MedImmune's Biologic Solution To Blocking IGF In Solid Tumors Heads Into Phase II Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
MIDI-573, which blocks insulin-like growth factor I and II while sparing receptors for normal glucose processing, heads into multiple Phase II studies this year accompanied by an assay to prospectively identify patient populations for further study, MedImmune head of oncology McMahon said in an April 4 interview at AACR.
You may also be interested in...
Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review
GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.
Pediatric Studies Of Difficult-To-Treat Cancers To Get Advisory Cmte. Review
GlaxoSmithKline's Votrient (pazopanib), Genentech's vismodegib and two investigational drugs will be the subjects for the Pediatric Oncology Subcommittee of FDA's Oncologic Drugs Advisory Committee Nov. 1.
MedImmune's Restructured Oncology Unit Displays Its Fruits At AACR
MedImmune's R&D reorganization into therapeutic business units takes the start-to-finish, integrated approach that has become trendy with big pharmas trying to capture the innovative spirit of small biotech – and the oncology pipeline will be a key test of how that restructuring delivers.